Sinobioway and F1 Oncology to Build Shenzhen CAR-T Manufacturing Facility

Shanghai Sinobioway Sunterra Biotech (SSSB) announced plans to extend its relationship with Florida 's F1 Oncology. SSSB will build a production facility, called Shenzhen Biowit, which will offer F1 Oncology's chemically defined suspension-based lentivirus manufacturing technology and processes to China's gene therapy market for CAR-T products and other gene therapies. One year ago, SSSB was formed by Sinobioway Group, Sunterra Capital and F1 Oncology to develop novel CAB (conditionally active biologic) CAR-T therapies for solid tumor malignancies in China . More details.... Share this with colleagues: // //